Over the next decade, the diagnosed incidence of breast
cancer (CaB) in Mexico will increase at almost three times the average annual
growth rate in the major pharmaceutical markets (United States, France, Germany,
Italy, Spain, United Kingdom, and Japan). This growing incident population and
the launches of several novel high-value agents will be the key drivers of
market growth for CaB in Mexico through 2016. Mexico’s lack of legal
requirement for clinical trials in the local population, as well as the
progressive and well-informed physician community, offers significant
opportunity to multinational companies (MNCs) with emerging therapies in this
indication. In this report, we examine the trends within Mexico’s CaB therapy
market, which is characterized by the widespread use of molecular testing, a
near-universal healthcare system, and the anticipated uptake of several
Primary research: 90 oncologists surveyed across Mexico. Separate in-depth interviews with 8 oncologists from Mexico.
Epidemiology: Total incident cases as well as progressed incidence cases of CaB in Mexico over a ten-year period (2011-2021) by age and stage.
Current therapies and medical practice: Reporting use of brands and generics for the CaB treatments available in Mexico.
Pricing and reimbursement: Prices of CaB therapies in Mexico versus other major markets and analysis of the impact of government reimbursement on treatment trends.
Market forecast features: Our analysis evaluates rates of CaB progression and rates of drug treatment with CaB therapies across all stages of the disease. We include a detailed forecast of current and emerging therapies within the categories of selective estrogen receptor modulators, aromatase inhibitors, selective estrogen receptor downregulators, antimetabolites and other cytotoxics, anthracyclines, antitubulins, HER2-targeting agents, angiogenesis inhibitors, and mTOR inhibitors from 2011 through 2016, using an epidemiology-based, bottom-up market model.